Want to see AU:CHM full AI Analyst Report?
Top Page
Chimeric Therapeutics Ltd.
(Sydney:CHM)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.04
â–²(310.00% Upside)
Action:Reiterated
Date:08/04/26
The score is primarily held down by weak financial performance—ongoing losses, negative operating/free cash flow, and a materially reduced equity cushion despite no reported debt. Technicals also detract, with the price below key moving averages and a negative MACD, though oversold readings offer a modest offset. Valuation contributes only slightly because the negative P/E is driven by unprofitability and dividend support is absent.
Positive Factors
Low Financial Leverage
Absence of reported debt in 2025 reduces fixed financing obligations and default risk, preserving flexibility to allocate cash to R&D or clinical programs. Structurally, low leverage eases near-term liquidity stress and supports pursuing partnerships or staged financing over the next several months.
Negative Factors
Persistent Cash Burn
Consistent negative operating and trailing free cash flow signal ongoing cash burn to fund development and operations. Structurally, this necessitates external financing or partnerships within months, elevating dilution risk, constraining discretionary spending, and limiting autonomous execution of clinical plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Absence of reported debt in 2025 reduces fixed financing obligations and default risk, preserving flexibility to allocate cash to R&D or clinical programs. Structurally, low leverage eases near-term liquidity stress and supports pursuing partnerships or staged financing over the next several months.
Read all positive factors
Chimeric Therapeutics Ltd. (CHM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$729.82K
Dividend YieldN/A
Average Volume (3M)3.63M
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue GrowthN/A
EPS Growth62.07%
CountryAU
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.56
Shares Outstanding81,091,610
10 Day Avg. Volume3,014,500
30 Day Avg. Volume3,625,345
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.74
Price to Sales (P/S)1.36
P/FCF Ratio-0.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$480.58M
Chimeric Therapeutics Ltd. Business Overview & Revenue Model
Company Description
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 020...
How the Company Makes Money
null...
Chimeric Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.57M | 3.97M | 7.46M | 4.51M | 2.62M | 2.65K |
| Gross Profit | 2.66M | 3.12M | 7.45M | 3.54M | 1.67M | -844.31K |
| EBITDA | -8.60M | -9.08M | -11.30M | -28.59M | -13.62M | -14.26M |
| Net Income | -15.00M | -10.43M | -12.53M | -25.92M | -15.90M | -15.11M |
Balance Sheet | ||||||
| Total Assets | 5.93M | 21.57M | 15.27M | 22.38M | 34.88M | 36.50M |
| Cash, Cash Equivalents and Short-Term Investments | 2.50M | 5.76M | 3.05M | 5.37M | 18.38M | 22.41M |
| Total Debt | 0.00 | 0.00 | 3.59M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 8.96M | 19.60M | 12.80M | 16.71M | 9.17M | 11.37M |
| Stockholders Equity | -3.03M | 1.97M | 2.47M | 5.66M | 25.71M | 25.13M |
Cash Flow | ||||||
| Free Cash Flow | -6.15M | -7.28M | 10.11K | -16.43M | -13.69M | -14.15M |
| Operating Cash Flow | -6.15M | -7.28M | -7.54M | -16.32M | -13.15M | -8.84M |
| Investing Cash Flow | -255.31K | 0.00 | 0.00 | -112.19K | -577.86K | -5.30M |
| Financing Cash Flow | 6.28M | 10.05M | 8.26M | 253.38K | 9.50M | 36.54M |
Chimeric Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$3.19B | -23.95 | -16.10% | ― | 555.67% | 49.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$12.36M | -2.50 | -161.62% | ― | -4.24% | 33.39% | |
44 Neutral | AU$729.82K | -0.02 | 2844.96% | ― | ― | 62.07% | |
43 Neutral | AU$21.29M | -17.47 | -49.25% | ― | ― | 25.00% | |
42 Neutral | AU$36.21M | -0.22 | -414.10% | ― | ― | -2.15% | |
40 Underperform | AU$73.69M | -0.87 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:CHM
Chimeric Therapeutics Ltd.
0.01
-0.16
-94.12%
AU:IMU
Imugene
0.07
-0.21
-75.44%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:MSB
Mesoblast Limited
2.46
0.44
21.78%
AU:IMM
Immutep Ltd
0.05
-0.18
-78.26%
AU:CMB
Regeneus Ltd.
0.42
-0.05
-10.64%
Chimeric Therapeutics Ltd. Corporate Events
Chimeric Therapeutics Reports Positive Trial Data and Launches Strategic Review
Jul 31, 2026
Chimeric Therapeutics Ltd. is an Australian cell therapy company developing advanced CAR T and NK cell treatments for solid and blood cancers, with flagship programs targeting gastrointestinal malignancies and acute myeloid leukemia. Its focus on ...
Chimeric Therapeutics Secures $1.62m R&D Tax Incentive Funding to Back Clinical Trials and Strategic Review
Jul 29, 2026
Chimeric Therapeutics has secured $1.62 million in funding from Endpoints Capital against its anticipated FY26 Research and Development Tax Incentive, providing early access to capital to support Phase 1/2 clinical trial activities and general wor...
Chimeric Flags Clinical and Regulatory Risks in Forward-Looking Disclaimer
Jul 28, 2026
Chimeric Therapeutics has issued a disclaimer emphasising that its presentation contains forward-looking statements, highlighting that actual outcomes may differ significantly due to various risks and uncertainties. The company notes potential del...
Chimeric Therapeutics Seeks ASX Quotation for 1.55m New Shares
Jul 22, 2026
Chimeric Therapeutics Limited has applied for quotation of 1,550,387 ordinary fully paid shares on the ASX, to be issued on July 22, 2026. The new securities arise from the exercise of options or conversion of other convertible instruments and wil...
Chimeric Therapeutics Seeks ASX Quotation for Additional Shares
Jul 14, 2026
Chimeric Therapeutics Limited has applied for quotation of 1,410,256 new ordinary fully paid shares on the ASX, with an issue date of 14 July 2026. The additional securities, arising from the exercise or conversion of existing instruments, will ma...
Chimeric Therapeutics Reports Expiry of 45,000 Unexercised Options
Jul 14, 2026
Chimeric Therapeutics has notified the market of the cessation of 45,000 listed options, CHMAY, which expired on July 13, 2026 without being exercised or converted. The expiry slightly reduces the company’s pool of potential future equity, b...
Chimeric Therapeutics Details Director Exit and Post-Consolidation Option Holdings
Jul 7, 2026
Chimeric Therapeutics Limited has announced the cessation of Eric Sullivan as a director, effective 6 July 2026. The company has lodged a Final Director’s Interest Notice with the ASX detailing Sullivan’s remaining interests in company...
Chimeric Therapeutics Board Member Eric Sullivan Retires
Jul 5, 2026
Chimeric Therapeutics announced that independent non-executive director Eric Sullivan has retired from its board, effective immediately, citing personal reasons. Sullivan, who joined the board in August 2023, had served as chairman of the Audit an...
Chimeric Therapeutics Seeks Quotation for 1.77 Million New ASX Shares
Jul 2, 2026
Chimeric Therapeutics Limited has applied for quotation on the ASX of 1,770,833 new ordinary fully paid shares under its CHM ticker. The securities are scheduled to be issued and quoted on July 2, 2026, expanding the company’s listed share b...
Chimeric Therapeutics Launches Adviser-Led Strategic Review to Unlock Value
Jul 1, 2026
Chimeric Therapeutics has appointed Hawkesbury Partners as an independent financial adviser to lead a structured strategic review aimed at maximising shareholder value. The move follows more than A$80 million of investment in clinical programs and...
Chimeric Therapeutics Seeks ASX Quotation for 733,333 New Shares
Jun 1, 2026
Chimeric Therapeutics Limited, an ASX-listed biotech company, focuses on developing therapeutic products for specialized healthcare markets. Its activities center on advancing novel treatments that can address unmet medical needs and support long-...
Chimeric posts positive early CHM CDH17 CAR-T data in metastatic GI cancers
May 31, 2026
Chimeric Therapeutics reported encouraging early-stage clinical results for its CHM CDH17 CAR-T therapy from a Phase 1/2 trial presented at the American Society of Clinical Oncology meeting. The study, involving heavily pre-treated metastatic gast...
Chimeric Therapeutics Seeks ASX Quotation for Additional Shares
May 12, 2026
Chimeric Therapeutics Ltd. has applied for quotation on the ASX of 313,291 new fully paid ordinary shares under the code CHM, with an issue date of May 11, 2026. The additional securities, issued as part of previously announced transactions, modes...
Chimeric Therapeutics Seeks ASX Quotation for New Share Issue
May 12, 2026
Chimeric Therapeutics has applied to the ASX for quotation of 512,820 new ordinary fully paid shares, which were issued on 11 May 2026. The application reflects the company’s ongoing use of equity securities, likely arising from the exercise...
Chimeric Therapeutics Plans Modest Share Placement on ASX
May 8, 2026
Chimeric Therapeutics has announced a proposed issue of up to 313,291 ordinary fully paid shares, to be conducted as a placement or similar type of securities issue on the ASX. The new shares are expected to be issued on May 11, 2026, which will m...
Chimeric Therapeutics Updates Capital Structure After Option Expiry
May 5, 2026
Chimeric Therapeutics has reported a change to its capital structure with the expiry of 26,238 listed options, identified as CHMAY, on 30 April 2026. The options lapsed without being exercised, resulting in a modest reduction in the number of pote...
Chimeric Therapeutics Issues 10 Million Long-Dated Unquoted Options
May 4, 2026
Chimeric Therapeutics Ltd. has notified the market of the issue of 10,000,000 unquoted options, exercisable at $0.50 and expiring on 31 December 2030. These securities, issued on 4 May 2026 under code CHMAAI, form part of a previously announced tr...
Chimeric Therapeutics Issues New Shares Under Corporations Act Disclosure Exemption
May 4, 2026
Chimeric Therapeutics has issued 6,900,993 new ordinary shares on 4 May 2026 under ASX code CHM without a prospectus, relying on provisions of the Corporations Act that allow certain placements without full disclosure. The company confirmed it is ...
Chimeric Therapeutics Seeks ASX Quotation for 6.9 Million New Shares
May 4, 2026
Chimeric Therapeutics Limited has applied for quotation on the ASX of 6,900,993 new ordinary fully paid shares, with an issue date of 4 May 2026. The newly issued securities form part of a previously announced transaction, signaling an expansion o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.